Story
FDA Plans to Appoint New Deputy Commissioners for Technology and Drugs, Report Says

The U.S. Department of Health and Human Services plans to appoint two new deputy commissioners at the Food and Drug Administration (FDA) to oversee technology and drugs, respectively, according to a CNBC report citing sources familiar with the plans.
Proposed Leadership Changes
The proposed restructuring would create two distinct senior roles. One deputy commissioner would focus on technology, including the rapidly evolving fields of artificial intelligence and digital healthcare. The other would have oversight of the agency's drug approval and regulation processes.
According to three people familiar with the matter cited in the report, Jared Seehafer is the leading candidate for the new technology-focused position. A candidate for the drug-focused role was not identified. The sources stressed that no final decisions have been made and the agency has not yet formally announced the appointments.
Context of Agency Transition
These potential changes come during a period of significant leadership transition at the FDA. Last week, President Donald Trump nominated White House policy aide Heidi Overton to lead the agency, an appointment that requires Senate confirmation. The previous FDA commissioner, Marty Makary, resigned in May after 13 months, reportedly following policy clashes with the White House.
AdSince May, Kyle Diamantas has served as acting FDA chief. Under his temporary leadership, the agency has re-examined several regulatory decisions, including reopening consideration for therapies from companies like Regenxbio, uniQure, and Replimune.
What This Means for the Industry
The creation of a deputy commissioner for technology underscores the growing importance of AI and data science in pharmaceutical development and medical device innovation. For investors and companies in the biotech and health-tech sectors, this could signal the FDA's intent to develop clearer regulatory pathways for products utilizing these advanced technologies.
A dedicated deputy for drugs could also aim to bring more stability and focus to the pharmaceutical approval process, which has recently been the subject of public disagreements involving companies such as Sarepta and Moderna.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.